Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May;30(3):411-423.
doi: 10.1080/14397595.2020.1718866. Epub 2020 Feb 3.

Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update

Ichiro Kobayashi  1 , Shinji Akioka  2 , Norimoto Kobayashi  3 , Naomi Iwata  4 , Shunichiro Takezaki  5 , Haruna Nakaseko  4 , Satoshi Sato  6 , Yutaka Nishida  7 , Tomo Nozawa  8 , Yuichi Yamasaki  9 , Kazuko Yamazaki  10 , Satoru Arai  11 , Ichizo Nishino  12 , Masaaki Mori  13
Affiliations
Free article
Review

Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update

Ichiro Kobayashi et al. Mod Rheumatol. 2020 May.
Free article

Erratum in

  • Correction.
    [No authors listed] [No authors listed] Mod Rheumatol. 2020 May;30(3):607. doi: 10.1080/14397595.2020.1764723. Mod Rheumatol. 2020. PMID: 32401116 No abstract available.

Abstract

Juvenile dermatomyositis is the most common type of juvenile idiopathic inflammatory myopathy mainly affecting the skin and proximal muscles. We have published the Japanese version of 'Clinical practice guidance for juvenile dermatomyositis (JDM) 2018 'consisting of a review of articles in the field and evidence-informed consensus-based experts' opinion on the treatment strategy in collaboration with The Pediatric Rheumatology Association of Japan and The Japan College of Rheumatology under the financial support by 'Research on rare and intractable diseases, Health and Labor Sciences Research Grants'. This article is a digest version of the Japanese guidance.

Keywords: Diagnosis; interstitial lung disease; management; myositis-specific autoantibodies; pathophysiology.

PubMed Disclaimer